There is 1 paper on AHA PREVENT risk score progression in aging research: 1 trial in people.
1 paper studies it1 finding
1 new paper in 30 daysSee all 1 papers on AHA PREVENT risk score progression
- Human trial1
Interventions
1Finerenone
downin humans1
1 study
Finerenone
downin humans1
Finerenone decreases AHA PREVENT risk score progression in humans (Base-model least squares mean difference −0.018 at Month 48; p<0.01; full-model reduction from Month 4, p<0.0001).
“Finerenone significantly reduced the progression of PREVENTTM score relative to placebo at Month 48 using the base model”
Human trialType 2 diabetes and chronic kidney disease without prior cardiovascular disease; base model versus placebo48 monthsn = 7,050
AHA Scientific Sessions 2026 abstract
Latest
1 paper in 12 monthsAHA Scientific Sessions 2026 Abstract
Efficacy of Finerenone in Primary Cardiovascular Prevention: A Mechanistic Analysis Using the AHA PREVENT™ Risk Score
Trial in 7,050 peopleFinerenone